TFDA had announced that product contains ergotamine needs to label warning statement

TFDA had currently (updated on 2024-04-02) announced that products contain ergotamine and dihydroergotamine need to label black box warning and its content with precaution. In addition, products contain ergometrine ( ergonovine ) and methylergometrine (methylergonovine) also need to label warning statement and precautions. The products contain bromocriptine need to label precautions on interactions.

If you need to confirm the regulation compliance for your label, you are welcome to contact us.